Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.82 |
| ▸ | RAF1 | P04049 | 10/20 | 0.76 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251276 | 0.90 | MAP2K1 (1.00) | MAP2K1RAF1SRCMAPK3MAPK1 | |
| SCHEMBL5011206 | 0.90 | MAP2K1 (0.67) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL5254847 | 0.88 | MAP2K1 (0.73) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL27707570 | 0.86 | MAP2K1 (1.00) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL6382750 | 0.86 | MAP2K1 (1.00) | MAP2K1RAF1SRCMAPK3MAPK1 | |
| SCHEMBL5256236 | 0.85 | MAP2K1 (0.77) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL4775969 | 0.85 | MAP2K1 (0.71) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL15320481 | 0.85 | MAP2K1 (0.77) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL6071665 | 0.85 | MAP2K1 (0.77) | MAP2K1RAF1SRCMAPK13MAP3K8 | |
| SCHEMBL22334734 | 0.85 | MAP2K1 (0.71) | MAP2K1RAF1MAPK3MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | claimed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | claimed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | claimed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | claimed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | claimed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | claimed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | MAP2K1 278/4885RAF1 115/4885SRC 104/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | MAP2K1 266/4885RAF1 135/4885SRC 117/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | MAP2K1 323/4885RAF1 115/4885SRC 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.